ArticleNature communications2020
Endocannabinoid signaling regulates the reinforcing and psychostimulant effects of ketamine in mice.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- Paradoxical role of the mesocorticolimbic Netrin1-DCC pathway in social competition and vulnerability to methamphetamine abuse during adolescence.Molecular psychiatry · 2026Article
- Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using wistar kyoto rats.Scientific reports · 2025Article
- KETAMIR-2, a new molecular entity and novel ketamine analog.Frontiers in pharmacology · 2025Article
- Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- How depression and antidepressant drugs affect endocannabinoid system?-review of clinical and preclinical studies.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- CB1 receptor mediates anesthetic drug ketamine‑induced neuroprotection against glutamate in HT22 cells.Experimental and therapeutic medicine · 2024Article
- CB1 Receptor Silencing Attenuates Ketamine-Induced Hyperlocomotion Without Compromising Its Antidepressant-Like Effects.Cannabis and cannabinoid research · 2023Article
- Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.Frontiers in psychiatry · 2023Article
- Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice.Nature communications · 2022Article
- Biomarkers of the Endocannabinoid System in Substance Use Disorders.Biomolecules · 2022Review
- The Src-Kinase Fyn is Required for Cocaine-Associated Memory Through Regulation of Tau.Frontiers in pharmacology · 2022Article
- Hsa-let-7d-5p Promotes Gastric Cancer Progression by Targeting PRDM5.Journal of oncology · 2022Article
- Simvastatin Blocks Reinstatement of Cocaine-induced Conditioned Place Preference in Male Mice with Brain Lipidome Remodeling.Neuroscience bulletin · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The abuse potential of ketamine limits its clinical application, but the precise mechanism remains largely unclear. Here we discovered that ketamine significantly remodels the endocannabinoid-related lipidome and activates 2-arachidonoylglycerol (2-AG) signaling in the dorsal striatum (caudate nucleus and putamen, CPu) of mice. Elevated 2-AG in the CPu is essential for the psychostimulant and reinforcing effects of ketamine, whereas blockade of the cannabinoid CB1 receptor, a predominant 2-AG receptor, attenuates ketamine-induced remodeling of neuronal dendrite structure and neurobehaviors. Ketamine represses the transcription of the monoacylglycerol lipase (MAGL) gene by promoting the expression of PRDM5, a negative transcription factor of the MAGL gene, leading to increased 2-AG production. Genetic overexpression of MAGL or silencing of PRDM5 expression in the CPu robustly reduces 2-AG production and ketamine effects. Collectively, endocannabinoid signaling plays a critical role in mediating the psychostimulant and reinforcing properties of ketamine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.